bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.02.25.706632

A Benchmarking Study of Feature Screening Approaches Across Omics Classification Settings

Abstract

In recent years, high dimensional omics analyses have become more commonplace for investigating complex biological systems. Typically, these studies attempt to identify key biomolecules associated with a particular biological process. Often, machine learning (ML) is used to identify these biomolecules, typically by learning which biomolecules are highly predictive of a treatment, biological outcome, or phenotype. A major challenge of applying ML to high throughput omics is overcoming noise when sample size is limited and unbalanced with respect to tens of thousands of biomolecules measured. Thus, feature selection (the process of reducing the number of predictors) is both a critical and common step in the ML analysis pipeline. While much attention has been given to embedding and wrapping techniques for feature selection in the omics space, filter-based methods for model-free feature selection have appealing theoretical properties. This manuscript evaluates sure screening, a class of filter-based feature selection methods which provide analytical guarantees for true feature set retention. Here, we cover existing feature screening methods based on the sure screening principal, available software, methods to improve feature screening, and contextualize feature screening in the larger discussion of feature selection for omics data analysis. Additionally, a suite of model-free sure screening approaches is applied and compared for several omics biomedical applications in a ML classification context. We identified BcorSIS as the most effective and computationally efficient screening method across various omics datasets, consistently outperforming others like CSIS and DCSIS in runtime. Author SummaryA common goal when analyzing high throughput omics data is to identify key biomolecules which may be important in complex biological systems. This type of large-scale analysis is critical, as it can significantly reduce the set of total biomolecules which are considered for more detailed, targeted analysis. Additionally, biomolecules which are highly predictive of specific phenotypes are useful markers to guide treatment. For instance, identifying which biomolecules are predictive of type 1 diabetes could improve early diagnosis, which may improve patient prognosis. However, modern instrumentation can often detect thousands or tens of thousands of biomolecules, and studies typically have a disproportionately limited number of samples. Many measured biomolecules, or features, are often noisy and uninformative, and overcoming this noise to identify an informative set of biomolecules can be challenging for machine learning (ML) models. Fortunately, there are many feature selection strategies which can intelligently reduce the number of "uninformative" biomolecules an ML model needs to overcome. In this work, sure screening, which is a class of feature selection methods that retains the true feature set under certain conditions, is evaluated in the context of omics data analyses. The pros and cons of various sure screening methods, including software availability, are summarized, and their use in the larger feature selection literature is contextualized. Additionally, we benchmark performance by applying a suite of sure screening approaches on several real omics datasets generated to understand the progression of type 1 diabetes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

VonKaenel, E., Bramer, L., Flores, J., Metz, T., Nakayasu, E. S., Webb-Robertson, B.-J.. 2026-02-26. A Benchmarking Study of Feature Screening Approaches Across Omics Classification Settings. https://doi.org/10.64898/2026.02.25.706632

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Senescence-associated KRAS upregulation in peripheral T cells links to premature coronary artery disease

Aims: Premature coronary artery disease (PCAD) lacks specific molecular drivers, and the role of immunosenescence is unclear. We investigated whether aging-related gene dysregulation in T cells contributes to PCAD. Methods: We combined bulk transcriptomics of PBMCs from 12 PCAD patients and 21 controls, single-cell RNA sequencing of PBMCs and human atherosclerotic plaques, weighted gene co-expression network analysis, gene perturbation network analysis, and molecular docking. Results: KRAS was identified as a hub gene intersecting PCAD-associated genes and aging-related genes. Single-cell analysis showed KRAS upregulation predominantly in effector CD8+ T cells, which exhibited the highest senescence scores that were further elevated in disease. Network perturbation of KRAS strongly impacted the cell killing pathway. KRAS-high effector CD8+ T cells were detected in coronary and carotid plaques, displaying enhanced cytotoxicity, exhaustion, and senescence features. Additionally, a candidate small molecule was computationally predicted to bind inactive KRAS. Conclusions: Elevated KRAS expression in senescent, cytotoxic CD8+ T cells is associated with PCAD, bridging immunosenescence and premature atherosclerosis. This finding provides a novel biomarker candidate and potential therapeutic entry point, awaiting further functional validation.

bioinformatics↗

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗